Client News

Home/Client News
Client News 2018-08-28T11:24:45+00:00
September 27, 2018
Galmed Pharmaceuticals to Present at the Cantor Global Healthcare Conference, ROTH Battle of the NASH Thrones Investor Conference and Stifel Healthcare Conference
TEL AVIV, Israel, Sept. 27, 2018 /PRNewswire/ --  Galmed Pharmaceuticals Ltd. (GLMD), a clinical-stage biopharmaceutical company focused on the development of the liver targeted SCD1 ...
September 27, 2018
Tyme Technologies, Inc. and the Joseph Ahmed Foundation Announce Planned Trial for SM-88 in Ewing’s Sarcoma
NEW YORK, Sept. 27, 2018 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (TYME) today announced that JAF will provide funding and patient support for an investigator-initiated ...
September 27, 2018
Checkpoint Therapeutics to Present at Ladenburg Thalmann 2018 Healthcare Conference
NEW YORK, Sept. 27, 2018 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (CKPT), a Fortress Biotech (FBIO) company, today announced that James F. Oliviero, President ...
September 27, 2018
Vaccinex, Inc. to Participate in Podium and Poster Sessions at the Fourth CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference
ROCHESTER, N.Y., Sept. 27, 2018 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (VCNX), a clinical-stage biotechnology company engaged in the discovery and development of targeted biotherapeutics to treat ...
September 27, 2018
Zealand Pharma has initiated the Phase 3 trial with dasiglucagon for treatment of severe hypoglycemia in children
Copenhagen, September 27, 2018 - Zealand Pharma A/S ("Zealand") (ZEAL), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, today ...
September 27, 2018
InspireMD Announces Presentation of Preliminary Cumulative Three-Year CGuard™ EPS Safety and Efficacy Data at the Transcatheter Cardiovascular Therapeutics 2018 Conference
TEL AVIV, Israel, Sept. 27, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention ...
September 27, 2018
Kuros Reports First Patient Treated in Randomized Controlled Trial of MagnetOs in Spinal Fusion
SCHLIEREN (ZURICH), Switzerland, Sept. 27, 2018 (GLOBE NEWSWIRE) -- Kuros Biosciences (SIX:KURN) today announced that the first patient has been treated in an investigator-led multicenter ...
September 27, 2018
Inventiva: First-half 2018 financial results and business update
Daix (France), September 27, 2018 - Inventiva S.A. ("Inventiva" or the "Company"), a biopharmaceutical company developing innovative therapies in nonalcoholic steatohepatitis (NASH), systemic sclerosis (SSc) ...
September 27, 2018
HTG Molecular Announces Extension to Precision Diagnostic Partnership (PDP) Program Three for Companion Diagnostic Submission
TUCSON, Ariz., Sept. 27, 2018 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (HTGM) (“HTG”), a provider of instruments, reagents, and services for molecular profiling applications, ...
September 26, 2018
HTG Molecular to Present a Corporate Overview at the Cantor Fitzgerald Global Healthcare Conference
TUCSON, Ariz., Sept. 26, 2018 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (HTGM) (HTG), a provider of instruments, reagents, and services for molecular profiling applications, ...
September 26, 2018
Genkyotex Exceeds Patient Enrollment Target in its Phase 2 Trial with GKT831 for Primary Biliary Cholangitis
Regulatory News: Genkyotex (GKTX.PA) (GKTX.PA) (Euronext Paris & Brussels: FR00011790542 – GKTX), a biopharmaceutical company and the leader in NOX therapies, announces today the completion of ...
September 26, 2018
Celyad Appoints Carri Duncan as Vice-President Corporate Development & Communications
MONT-SAINT-GUIBERT, Belgium, Sept. 26, 2018 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and NASDAQ: CYAD), a clinical-stage biopharmaceutical company focused on the development of ...
September 26, 2018
EDAP TMS SA : Houston Methodist Medical Center Research Study Sheds Positive Light on Use of HIFU for Localized Prostate Cancer
AUSTIN, TX - LYON, France, September 26, 2018 - EDAP TMS (EDAP) today announced the results of a study conducted at Houston Methodist Medical Center ...
September 26, 2018
Foamix Pharmaceuticals to Participate in the Cantor Fitzgerald Global Healthcare Conference
REHOVOT, Israel and BRIDGEWATER, N.J., Sept. 26, 2018 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (FOMX), a clinical-stage specialty pharmaceutical company focused on developing and commercializing ...
September 26, 2018
Aimmune Therapeutics to Present at the Cantor Global Healthcare Conference on Wednesday, October 3
BRISBANE, Calif.--(BUSINESS WIRE)--Aimmune Therapeutics, Inc. (AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that President and CEO Jayson Dallas, M.D., will ...
September 26, 2018
Molecular Templates to Present at the Ladenburg Thalmann and Cantor Healthcare Conferences
AUSTIN, Texas, Sept. 26, 2018 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (MTEM), a clinical-stage oncology company focused on the discovery and development of the company’s ...
September 26, 2018
AIT Therapeutics to Present at the Ladenburg 4th Annual Healthcare Conference
NEW YORK, Sept. 26, 2018 (GLOBE NEWSWIRE) -- AIT Therapeutics, Inc. (AITB), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide ...
September 26, 2018
Opiant Pharmaceuticals to Present at the Cantor Global Healthcare Conference
SANTA MONICA, Calif., Sept. 26, 2018 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions and drug overdose, ...
September 26, 2018
Zosano Pharma Enters Into Capital Equipment Lease Agreement With Trinity Capital Investment
FREMONT, Calif., Sept. 26, 2018 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (ZSAN) (“Zosano” or the “Company”), a clinical-stage biopharmaceutical company developing and commercializing therapies that deliver ...
September 26, 2018
Novus Therapeutics to Present at the Ladenburg Thalmann 2018 Healthcare Conference
IRVINE, Calif.--(BUSINESS WIRE)--Novus Therapeutics, Inc. (NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (“ENT”), ...
Page 25 of 128